<DOC>
	<DOCNO>NCT02370251</DOCNO>
	<brief_summary>This single-assignment study evaluate whether Omegaven ( IV fish oil ) effective treat liver disease child long-term IV nutrition .</brief_summary>
	<brief_title>Compassionate Use Omegaven Children</brief_title>
	<detailed_description>Children 18 year age , parenteral nutrition , direct bilirubin level 2 mg/dL great eligible receive Omegaven maximum dose 1 g/kg/day . Up 200 child eligible enrollment . Direct bilirubin level labs monitor well growth parameter .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Gastroschisis</mesh_term>
	<mesh_term>Infant , Premature , Diseases</mesh_term>
	<mesh_term>Intestinal Atresia</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>Bilirubin</mesh_term>
	<criteria>Live temporarily relocate Oklahoma Age less 18 year , sex , race Have direct bilirubin level â‰¥2 mg/dL two consecutive week least 14 day parenteral nutrition Received parenteral lipid maximum dose 1.5 g/kg/day ( 21 g/kg two week prior ) Are currently enrol another lipid emulsion study Known food allergy fish Known metabolic disorder lipid metabolism Active coagulopathies ( active bleeding require blood product treatment prior 48 hour ) Medical condition likely result death next 30 day</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fat Emulsions , Intravenous</keyword>
	<keyword>Parenteral-Nutrition-Associated Liver Disease</keyword>
	<keyword>Cholestasis</keyword>
	<keyword>Omegaven</keyword>
	<keyword>Fish Oil</keyword>
</DOC>